Hikma Pharmaceuticals (LON:HIK) Share Price Crosses Below Two Hundred Day Moving Average - What's Next?

Key Points

• Technical: Shares crossed below their two hundred day moving average (200‑DMA GBX 1,535.53), trading as low as GBX 1,335 and last at GBX 1,348 on volume 717,466, signalling a near‑term bearish technical shift.
• Analysts: The stock has an average rating of "Buy" from five analysts with an average target of GBX 2,326, and recent notes include Berenberg raising its target to GBX 2,300 and Deutsche Bank keeping a Buy at GBX 2,400—implying substantial upside from current levels.
• Fundamentals: Hikma's market cap is £2.92 billion with a P/E of 7.45 and PEG of 2.38, but a debt‑to‑equity ratio of 63.59 that investors should consider alongside the valuation and analyst optimism.

Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,535.53 and traded as low as GBX 1,335. Hikma Pharmaceuticals shares last traded at GBX 1,348, with a volume of 717,466 shares.

Wall Street Analyst Weigh In

HIK has been the subject of a number of research analyst reports. Berenberg Bank raised their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,300 and gave the stock a "buy" rating in a research note on Wednesday, March 4th. Deutsche Bank Aktiengesellschaft dropped their price target on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a "buy" rating for the company in a research note on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Hikma Pharmaceuticals presently has an average rating of "Buy" and an average target price of GBX 2,326.

Hikma Pharmaceuticals Price Performance

The business has a 50 day moving average of GBX 1,367.64 and a 200 day moving average of GBX 1,535.53. The company has a market cap of £2.92 billion, a PE ratio of 7.45, a price-to-earnings-growth ratio of 2.38 and a beta of 0.61. The company has a debt-to-equity ratio of 63.59, a current ratio of 1.82 and a quick ratio of 1.27.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.